2024
The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionThe impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024, 119: 1585-1596. PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patients
2022
Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirus
2020
The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatment
2016
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment
Bojko MJ, Mazhnaya A, Marcus R, Makarenko I, Islam Z, Filippovych S, Dvoriak S, Altice FL. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment. Journal Of Substance Use And Addiction Treatment 2016, 66: 37-47. PMID: 27211995, PMCID: PMC4919997, DOI: 10.1016/j.jsat.2016.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidDelivery of Health CareFemaleFocus GroupsGrounded TheoryHumansMaleOpiate Substitution TreatmentOpioid-Related DisordersPatient Acceptance of Health CarePractice Guidelines as TopicPractice Patterns, Physicians'Quality ImprovementSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyOAT retentionAgonist therapyTreatment goalsAdditional patient educationRealistic treatment goalsPrimary care settingQuality improvement interventionsCommunity-level barriersPatient educationOpioid addictionCare settingsTreatment retentionMultilevel barriersTreatment settingsImprovement interventionsPWIDMedical staffTherapyTreatmentCommunity awarenessDelivery barriersExperiences of PWIDHigh attritionFocus groups
2013
Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine
Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. International Journal Of Drug Policy 2013, 24: e91-e98. PMID: 24360402, PMCID: PMC5553122, DOI: 10.1016/j.drugpo.2013.09.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAntitubercular AgentsDelivery of Health Care, IntegratedDrug UsersFemaleHealth Knowledge, Attitudes, PracticeHeroin DependenceHumansInpatientsMaleMedication AdherenceMethadoneOpiate Substitution TreatmentProspective StudiesRisk FactorsTime FactorsTreatment OutcomeTuberculosisUkraineConceptsTB medication adherenceMethadone maintenanceTB treatmentMedication adherenceTreatment discontinuationMulti-drug resistant tuberculosisInpatient TB treatmentNumerous treatment challengesTB treatment completionOnly independent predictorOpioid-dependent patientsIndependent predictorsPrimary outcomeOpioid dependenceResistant tuberculosisMethadone treatmentTB facilitiesTreatment optionsDependent patientsTuberculosis treatmentTreatment completionTreatment challengesObservational studyMMT groupTreatment retention
2011
Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIV